

The Establishment of Negotiation Committee, Therapeutic Guidelines and HTA Efforts in CEE Countries THE CASE OF GREECE



Magda Chatzikou, PhD, Managing Partner PharmEcons Easy Access Ltd
Lecturer at Open University of Greece



Overview of refugee crisis



| MAx&PA update | Thanos Sakorafas | Cycle meeting | Sep 2016 | For Internal Use Only

- ❖ More than 1mio people reached EU in '15 and ~ 292,079 have arrived so far in '16.
- ❖ FYROM, Serbia, Croatia and Austria have closed their borders, leaving more than 59k migrants & refugees trapped in GR.
- ❖ Agreement reached between the EU and Turkey on 18 MAR stipulates that anyone who arrived in Greece via Turkey after 20 MAR must be held until their papers are processed and those deemed ineligible are to be sent back to Turkey.
- ❖ However, the implementation of the agreement, especially following the recent attempted coup in Turkey, remains problematic.
- ❖ Due to last MD for uninsured, migrants could potentially have full access to NHS and pharmaceutical treatment, though w/o additional budget

Political & Fiscal Environment

Political Stability

- ✓ Greece continues to be impacted by the economic and migration crises
- ✓ Government cohesion is directly associated with the progress of the economy and the management of the migration crisis, as well as the fatigue of the SYRIZA & ANEL ruling parties

Funding

Following the approval of the second set of prerequisite measures on 22 MAY, GR has been funded €10,3 bn out of which, €7,5 bn used for arrears payments

The last part of €2,8bn (€1,8bn for arrears) were disbursed in sub-tranches subjected to milestones related to privatization.

Debt relief: The agreement paves the way for a debt relief agreement starting in 2018.

Priorities of the GR Government in Health Care based on the latest MoU

1	Expenditure Rationalization	<ul style="list-style-type: none"> • Tenders • Spending excess reduction • Price volume agreements / Unified Rebate • Therapeutic Protocols and prescription guidelines • Health Technology Assessment
2	Generics penetration	<ul style="list-style-type: none"> • Incentives at pharmacists ' level • Public campaign on Generics • Revision of Prescription targets for doctors • Gx inpatient & outpatient share increase
3	Financial Mng of Hospitals	<ul style="list-style-type: none"> • Annual external financial audits • Adoption of DRG
4	Transparency / Monitoring	<ul style="list-style-type: none"> • Monthly reports on HC expenditure; and on hospital financial data • Activity related indicators and financial data for hospitals (Quarterly); • Hospital performance comparison (Annual); • Human resources for the whole health care sector (Annual);
5	Operational Excellence	<ul style="list-style-type: none"> • Monitor Progress (new protocols, registries and prescription guidelines) • Execute the claw backs every six months and perform regular audits / Update on a regular basis the positive and the negative list • Timely Arrears payment to industry


Pharmaceutical Expenditure & Rebates Evolution



*Latest data EOPYY, March 2016


5

Priorities of the State & The Industry



HC Environment in 2017 – MoU Imposed Measures

...Towards an HTA country



Thank you for your attention